Resmed Inc
Resmed
RMD · NYSE
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $5.7B
- Assets
- $9B
- SEC filing
- DEF 14A
- Filed
- October 2, 2025
Executive Compensation
Compensation reported for Resmed’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Michael Farrell
Chief Executive Officer
$14.7M
Reported total
- Salary
- $1,214,150
- Stock awards
- $8,775,059
- Incentives
- $1,646,743
- Option awards
- $2,925,007
- Other
- $113,584
Justin Leong
Chief Product Officer
$3.9M
Reported total
- Salary
- $677,032
- Stock awards
- $2,600,037
- Incentives
- $552,478
- Option awards
- $0
- Other
- $81,894
Bobby Ghoshal
Chief Commercial Officer, Residential Care Software
$3.7M
Reported total
- Salary
- $651,660
- Stock awards
- $2,400,078
- Incentives
- $550,001
- Option awards
- $0
- Other
- $50,716
Brett Sandercock
Chief Financial Officer
$3.6M
Reported total
- Salary
- $498,967
- Stock awards
- $2,600,037
- Incentives
- $407,171
- Option awards
- $0
- Other
- $65,835
Mike Rider
Global General Counsel And Secretary
$2.3M
Reported total
- Salary
- $508,745
- Stock awards
- $1,400,005
- Incentives
- $311,363
- Option awards
- $0
- Other
- $69,009
Michael Farrell
Chief Executive Officer
$14.7M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed October 2, 2025.
- Salary
- $1.2M
- Stock Awards
- $8.8M
- Option Awards
- $2.9M
- Incentives
- $1.6M
- Other
- $114K
Historical Compensation
Michael Farrell total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,214,150 | $8,775,059 | $14,674,543 |
| 2024 | $1,168,987 | $8,400,057 | $14,120,829 |
| 2023 | $1,128,211 | $8,249,986 | $13,868,641 |
Named Executive Officers
Michael Farrell
Chief Executive Officer
Resmed · RMD
$14.7M
FY 2025 · DEF 14A
Bobby Ghoshal
Chief Commercial Officer, Residential Care Software
Resmed · RMD
$3.7M
FY 2025 · DEF 14A
Justin Leong
Chief Product Officer
Resmed · RMD
$3.9M
FY 2025 · DEF 14A
Mike Rider
Global General Counsel And Secretary
Resmed · RMD
$2.3M
FY 2025 · DEF 14A
Brett Sandercock
Chief Financial Officer
Resmed · RMD
$3.6M
FY 2025 · DEF 14A
Source information
- Company
- Resmed Inc
- Ticker
- RMD · NYSE
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- October 2, 2025
- SEC accession number
- 0000943819-25-000079
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company